Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.58 |
| ▸ | HTR1A | P08908 | 1/20 | 0.56 |
| ▸ | DRD2 | P14416 | 1/20 | 0.56 |
| ▸ | HTR2A | P28223 | 1/20 | 0.56 |
| ▸ | HRH1 | P35367 | 1/20 | 0.56 |
| ▸ | DRD3 | P35462 | 1/20 | 0.56 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6946206 | 0.95 | KDM4E (0.65) | KDM4EALDH1A1SMN1; SMN2HRH3HTR1A | |
| SCHEMBL8114904 | 0.90 | LTA4H (0.61) | KDM4EALDH1A1SMN1; SMN2HRH3TMEM97 | |
| SCHEMBL6945688 | 0.90 | LTA4H (0.61) | KDM4EALDH1A1SMN1; SMN2HRH3TMEM97 | |
| SCHEMBL9057922 | 0.84 | LMNA (0.70) | ALDH1A1SMN1; SMN2HRH3HTR1ADRD2 | |
| SCHEMBL6655573 | 0.84 | KMT2A (0.60) | KDM4EALDH1A1HRH3DRD2DRD3 | |
| SCHEMBL491672 | 0.83 | HRH3 (0.79) | KDM4EALDH1A1SMN1; SMN2HRH3HRH1 | |
| SCHEMBL15920898 | 0.81 | HRH3 (0.82) | KDM4EALDH1A1SMN1; SMN2HRH3HRH1 | |
| SCHEMBL492176 | 0.81 | HRH3 (0.79) | KDM4EALDH1A1SMN1; SMN2HRH3 | |
| SCHEMBL491550 | 0.81 | HRH3 (0.79) | KDM4EALDH1A1SMN1; SMN2HRH3 | |
| SCHEMBL7033807 | 0.81 | HTR1A (0.80) | KDM4EALDH1A1SMN1; SMN2HRH3HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090029958-A1 | PHENETHANOLAMINE DERIVATIVES AS BETA2 ADRENORECEPTOR AGONISTS | ASTRAZENECA AB (SE) | 2009-01-29 | — | — | US | disclosed |
| EP-2013197-A1 | PHENETHANOLAMINE DERIVATIVES AS BETA2 ADRENORECEPTOR AGONISTS | AstraZeneca AB (SE) | 2009-01-14 | — | — | EP | disclosed |
| WO-2007102771-A1 | PHENETHANOLAMINE DERIVATIVES AS BETA2 ADRENORECEPTOR AGONISTS | ASTRAZENECA AB (SE) | 2007-09-13 | — | — | WO | disclosed |
| US-5760035-A | PIPERIDINE COMPOUNDS SUBSTITUTED WITH AN AMINOALKYL GROUP AND AN ARYLOXYALKYL GROUP, ANTIALLERGENS, ANTIINFLAMMATORY AGENTS, IMMUNOSUPPRESSANTS | KNOLL AKTIENGESELLSCHAFT (DE) | 1998-06-02 | — | — | US | disclosed |
| EP-0720602-B1 | 4-ALKYLAMINO-1-PHENOXYALKYL PIPERIDINES AS ANTIINFLAMMATORY, ANTIALLERGIC AND IMMUNOMODULATING AGENTS | KNOLL AG (DE) | 1997-07-09 | — | — | EP | disclosed |
| EP-0720602-A1 | 4-ALKYLAMINO-1-PHENOXYALKYL PIPERIDINES AS ANTIINFLAMMATORY, ANTIALLERGIC AND IMMUNOMODULATING AGENTS | KNOLL AG (DE) | 1996-07-10 | — | — | EP | disclosed |
| WO-1995008535-A1 | 4-ALKYLAMINO-1-PHENOXYALKYL PIPERIDINES AS ANTIINFLAMMATORY, ANTIALLERGIC AND IMMUNOMODULATING AGENTS | KNOLL AG (DE) | 1995-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090029958-A1 | PHENETHANOLAMINE DERIVATIVES AS BETA2 ADRENORECEPTOR AGONISTS | ADRB2, ADRB1, ADRA2A | KDM4E 3961/4885ALDH1A1 2322/4885SMN1; SMN2 4328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.